Sudeep Pharma IPO to Open on November 21, Aiming to Raise ₹895 Crore

Sudeep Pharma is set to open its initial public offering on November 21, marking its maiden entry into the public markets. The company has announced a price band of 563 to 593 per share for the issue.

IPO Structure and Fundraising Plan

Sudeep Pharma plans to raise 895 crore through a combination of fresh issue and offer for sale. The fresh issue consists of 1.6 million equity shares totalling 95 crore, while the offer for sale includes 13.5 million shares worth 800 crore.

The promoters selling shares in the offering are Sujit Jaysukh Bhayani, Sujeet Jaysukh Bhayani HUF, Shanil Sujit Bhayani, and Avani Sujit Bhayani. As per the red herring prospectus, not more than 50% of the IPO will be allotted to qualified institutional buyers, not less than 35% to retail investors, and not less than 15% to non-institutional investors.

Company Overview

Incorporated in 1989, Sudeep Pharma is engaged in manufacturing pharmaceutical excipients, food-grade minerals, and speciality nutrition ingredients. The firm caters to customers across more than 100 countries and services industries including pharmaceuticals, food, and nutrition.

The company operates six manufacturing facilities with a combined capacity of 50,000 metric tonnes. Its mineral portfolio includes calcium, iron, magnesium, zinc, potassium, and sodium ingredients. Over the years, Sudeep Pharma has developed a diversified product range catering to both domestic and international markets.

Key IPO Dates, Lot Size, and Management Details

The Sudeep Pharma IPO will open for bidding on Friday, November 21, and close on Tuesday, November 25, 2025. Anchor investors will participate one day prior, on November 20. The basis of allotment is expected on Wednesday, November 26, with the listing tentatively scheduled for Friday, November 28 on both the NSE and BSE.

The minimum lot size for retail investors is 25 shares. At the upper end of the price band, one lot would cost 14,825 and bids can be made in multiples of the lot size. MUFG Intime India will act as the registrar of the issue, while ICICI Securities and IIFL Capital Services are the book-running lead managers.

Read More: Upcoming IPOs This Week, 17–21 Nov 2025.

Conclusion

Sudeep Pharma’s IPO brings a long-established excipients and minerals manufacturer to the public markets with a defined fundraising plan. Investor interest will now focus on subscription trends when the issue opens on November 21.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.